Literature DB >> 17581744

The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.

M J Fell1, N Anjum, K Dickinson, K M Marshall, L M Peltola, S Vickers, S Cheetham, J C Neill.   

Abstract

INTRODUCTION: Treatment with some antipsychotic drugs may result in excessive body weight gain which can have detrimental effects on patient compliance, morbidity and mortality. The aim of the present study was to investigate the effect of atypical antipsychotic drugs on dietary macronutrient selection, body weight, body composition and biochemical parameters related to obesity in female rats.
MATERIALS AND METHODS: Forty pair-housed, adult female hooded-Lister rats (250 +/- 5 g) were habituated to three diets containing principally protein, fat, or carbohydrate in a home cage self-selection paradigm. Olanzapine (2 mg/kg), risperidone (0.5 mg/kg), ziprasidone (2.5 mg/kg), or vehicle was injected intraperitoneally once daily for 22 days; food selection, water intake, and body weight were recorded daily, while body composition and plasma hormones (insulin, glucose, nonesterified free fatty acid, total cholesterol, glycerol, triacylglycerol, leptin, and prolactin) were analyzed at the end of the study.
RESULTS: Only olanzapine significantly increased body weight and food intake. Macronutrient selection was significantly altered after olanzapine and risperidone treatment (increased protein and decreased fat preference). Only olanzapine increased carcass fat content. Locomotor activity was significantly reduced in all treatment groups. Both olanzapine and risperidone significantly increased plasma prolactin. Olanzapine was without effect on any other biochemical parameter measured. Ziprasidone significantly reduced plasma leptin and nonsignificantly reduced NEFA, while risperidone significantly reduced fasting plasma glucose.
CONCLUSION: This study supports our previous work demonstrating weight gain and increased feeding behavior induced by olanzapine and could have important implications for enhancing our understanding of the mechanisms by which olanzapine and other atypical antipsychotics induce weight gain in the clinic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581744     DOI: 10.1007/s00213-007-0833-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  53 in total

1.  Studies on modulation of feeding behavior by atypical antipsychotics in female mice.

Authors:  Gurpreet Kaur; Shrinivas K Kulkarni
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-02       Impact factor: 5.067

2.  Body weight gain after administration of antipsychotic drugs.

Authors:  Trino Baptista; A Lacruz; D De Mendoza; J M Mendoza; R Silvera; F Angeles; M T Mendoza; L Hernandez
Journal:  Pharmacopsychiatry       Date:  2002-01       Impact factor: 5.788

3.  Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection.

Authors:  Julie Minet-Ringuet; Patrick C Even; Benjamin Guesdon; Daniel Tomé; Renaud de Beaurepaire
Journal:  Behav Brain Res       Date:  2005-09-08       Impact factor: 3.332

4.  Amitriptyline, weight gain and carbohydrate craving: a side effect.

Authors:  E S Paykel; P S Mueller; P M De la Vergne
Journal:  Br J Psychiatry       Date:  1973-11       Impact factor: 9.319

5.  Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats.

Authors:  M J Fell; R Gibson; E McDermott; G Sisodia; K M Marshall; J C Neill
Journal:  Behav Brain Res       Date:  2005-01-17       Impact factor: 3.332

6.  Novel antipsychotics: comparison of weight gain liabilities.

Authors:  D A Wirshing; W C Wirshing; L Kysar; M A Berisford; D Goldstein; J Pashdag; J Mintz; S R Marder
Journal:  J Clin Psychiatry       Date:  1999-06       Impact factor: 4.384

7.  Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats.

Authors:  M J Fell; J C Neill; K M Marshall
Journal:  Eur Neuropsychopharmacol       Date:  2004-10       Impact factor: 4.600

8.  The effects of pregnancy and lactation on dietary self-selection in the rat.

Authors:  J Dial; D D Avery
Journal:  Physiol Behav       Date:  1991-04

9.  Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.

Authors:  M J Fell; K M Marshall; J Williams; J C Neill
Journal:  J Psychopharmacol       Date:  2004-06       Impact factor: 4.153

10.  Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.

Authors:  Julie Minet-Ringuet; Patrick C Even; Marc Goubern; Daniel Tomé; Renaud de Beaurepaire
Journal:  Appetite       Date:  2006-03-23       Impact factor: 3.868

View more
  22 in total

1.  Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.

Authors:  Heidi N Boyda; Ric M Procyshyn; Lurdes Tse; Erin Hawkes; Chen H Jin; Catherine C Y Pang; William G Honer; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2012-11       Impact factor: 6.186

2.  GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.

Authors:  Ajaykumar N Sharma; Sagar S Ligade; Jay N Sharma; Praveen Shukla; Khalid M Elased; James B Lucot
Journal:  Metab Brain Dis       Date:  2014-07-15       Impact factor: 3.584

3.  Increased consumption of ethanol and sugar water in mice lacking the dopamine D2 long receptor.

Authors:  Zachary B Bulwa; Jordan A Sharlin; Peter J Clark; Tushar K Bhattacharya; Chessa N Kilby; Yanyan Wang; Justin S Rhodes
Journal:  Alcohol       Date:  2011-07-31       Impact factor: 2.405

4.  Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression.

Authors:  Shu-Juan Pan; Yun-Long Tan; Shang-Wu Yao; Yu Xin; Xuan Yang; Jing Liu; Jing Xiong
Journal:  Acta Pharmacol Sin       Date:  2018-05-10       Impact factor: 6.150

5.  Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis.

Authors:  Robert K McNamara; Jessica A Able; Ronald Jandacek; Therese Rider; Patrick Tso
Journal:  Schizophr Res       Date:  2008-11-07       Impact factor: 4.939

6.  Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

Authors:  Nima Davoodi; Mikhail Kalinichev; Sergei A Korneev; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

7.  Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.

Authors:  V L Albaugh; J G Judson; P She; C H Lang; K P Maresca; J L Joyal; C J Lynch
Journal:  Mol Psychiatry       Date:  2010-03-23       Impact factor: 15.992

8.  Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.

Authors:  Montserrat Victoriano; Dominique Hermier; Patrick C Even; Gilles Fromentin; Jean-François Huneau; Daniel Tomé; Renaud de Beaurepaire
Journal:  Psychopharmacology (Berl)       Date:  2009-07-02       Impact factor: 4.530

9.  Chronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability.

Authors:  Hiren R Modi; Ameer Y Taha; Hyung-Wook Kim; Lisa Chang; Stanley I Rapoport; Yewon Cheon
Journal:  J Neurochem       Date:  2012-12-06       Impact factor: 5.372

10.  Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.

Authors:  Shona L Kirk; John Glazebrook; Ben Grayson; Joanna C Neill; Gavin P Reynolds
Journal:  Psychopharmacology (Berl)       Date:  2009-08-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.